Comparing Novo Nordisk A/S (NYSE:NVO) and Pasithea Therapeutics (NASDAQ:KTTA)

Novo Nordisk A/S (NYSE:NVO) and Pasithea Therapeutics (NASDAQ:KTTA) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, risk, profitability, dividends and valuation.

Profitability

This table compares Novo Nordisk A/S and Pasithea Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Novo Nordisk A/S	34.86%	87.43%	28.01%
Pasithea Therapeutics	N/A	-74.56%	-67.62%

Volatility and Risk

Novo Nordisk A/S has a beta of 0.42, meaning that its share price is 58% less volatile than the S&P 500. Comparatively, Pasithea Therapeutics has a beta of 0.74, meaning that its share price is 26% less volatile than the S&P 500.

Insider & Institutional Ownership

11.5% of Novo Nordisk A/S shares are owned by institutional investors. Comparatively, 23.9% of Pasithea Therapeutics shares are owned by institutional investors. 0.1% of Novo Nordisk A/S shares are owned by company insiders. Comparatively, 16.3% of Pasithea Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Novo Nordisk A/S and Pasithea Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novo Nordisk A/S	$258.00 billion	2.06	$12.15 billion	$2.90	40.75
Pasithea Therapeutics	$20,000.00	246.67	-$15.96 million	N/A	N/A

Novo Nordisk A/S has higher revenue and earnings than Pasithea Therapeutics.

Analyst Recommendations

This is a breakdown of recent ratings for Novo Nordisk A/S and Pasithea Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novo Nordisk A/S	0	1	6	0	2.86
Pasithea Therapeutics	0	0	0	0	N/A

Novo Nordisk A/S presently has a consensus target price of $145.17, indicating a potential upside of 22.85%. Given Novo Nordisk A/S’s higher possible upside, analysts clearly believe Novo Nordisk A/S is more favorable than Pasithea Therapeutics.

Summary

Novo Nordisk A/S beats Pasithea Therapeutics on 7 of the 11 factors compared between the two stocks.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

About Pasithea Therapeutics

Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.